Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
sectral
Synonyms :
acebutolol
Class :
Anti arrhythmias II, beta blocker
Brand Name :
sectral
Synonyms :
acebutolol
Class :
Anti arrhythmias II, beta blocker
Dosage Forms & Strengths
Capsule
200mg
400mg
400 - 1200
mg/day
Capsule
Orally 
every 12 hours
Do not exceed 1200mg/day
400 - 1200
mg/day
Capsule
Orally 
every 12 hours
400 - 1200
mg/day
capsule
Orally 
every 12 hours
Do not exceed 1200mg/day
Safety and efficacy not established
Initial dose: 200-400mg/day divided orally. Do not exceed 800mg/day
Initial dose: 200-400mg/day divided orally
Do not exceed 800mg/day
Initial dose: 200-400mg/day divided orally
Do not exceed 800mg/day
may increase the hypotensive effect of anti-hypertensives
may increase the bradycardic effect
may increase the bradycardic effect of beta blockers
may increase the bradycardic effect of bradycardiac agents
may increase the hypotensive effect of anti-hypertensives
may increase the bradycardic effect of bradycardiac agents
may increase the therapeutic effect of beta blockers
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
may decrease the antihypertensive activity
may increase the AV blocking effect of alpha2 agonists
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may have an increased bradycardic effect when combined with beta-blockers
may decrease the therapeutic effect when combined with tasimelteon
may have an increased bradycardic effect when combined with siponimod
may increase the QTc-prolonging effect of each other when combined
may have an increased AV-blocking effect when combined with beta-blockers
cinnarizine and dimenhydrinateÂ
this is combination is contraindicated in patients with cardiovascular diosrdrs who are on antiarrhythmic drugs
bloodroot along with anti-arrhythmic medications will result in irregularity in heartbeat and bradycardia
may decrease the bronchodilatory effect
may increase the hypotensive effect of anti-hypertensives
may enhance the arrhythmogenic effect of bradycardia-causing agents
may increase the bradycardic effect of beta blockers
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
it may enhance the effects when combined with lofexidine by pharmacodynamic synergism
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with Beta2-Agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the bronchodilatory effect when combined with beta2-agonists
may decrease the antihypertensive effect when both drugs are combined
may enhance the anti-hypertensive effect when both drugs are combined
may decrease the bronchodilatory effect
it increases the effect of bradycardia of Beta-Blockers
may have an increased bradycardic effect when combined with beta-blockers
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
may decrease the bronchodilatory effect of beta2-agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
may enhance the orthostatic hypotensive effect of alpha1-blockers
bunazosin (Not available in the United States)
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
it increases the effect of hypoglycemia of antidiabetic agents
it increases the effect of hypoglycemia of antidiabetic agents
it increases the effect of hypoglycemia of antidiabetic agents
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may increase the bradycardic effect of beta blockers
may increase the bradycardic effect of beta blockers
may increase the bradycardic effect of beta blockers
may increase the bradycardic effect of beta blockers
may increase the bradycardic effect of beta blockers
may increase the bradycardic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypotensive effect of beta blockers
may increase the hypotensive effect of beta blockers
may increase the hypotensive effect of beta blockers
may increase the hypotensive effect of beta blockers
may increase the hypotensive effect of beta blockers
may increase the hypotensive effect of anti-hypertensives
may increase the hypotensive effect of anti-hypertensives
may increase the hypotensive effect of anti-hypertensives
may increase the hypotensive effect of anti-hypertensives
may increase the hypotensive effect of anti-hypertensives
may increase the serum concentration of beta blockers
may increase the bradycardic effect
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect of beta blockers
may decrease the bronchodilatory effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the hypoglycemic effect of beta blockers
may increase the effect of alpha1-blockers
bunazosin (Not available in the United States)
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may have an increased hypoglycemic effect when combined with antidiabetic agents
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with ergot derivatives
may have an increased vasoconstricting effect when combined with ergot derivatives
it may diminish the metabolism when combined with azelastine
when netupitant is combined with acebutolol, it can lead to a reduced metabolism of acebutolol
acebutolol has the potential to enhance the arrhythmogenic effects of mibefradil
batefenterol (Investigational)Â
The combination of batefenterol with acebutolol may reduce the therapeutic effiectiveness of batefenterol
antipyrine has been observed to potentially reduce the antihypertensive effects of acebutolol
The arrhythmogenic effects of ajmaline might be intensified by acebutolol
The Therapeutic effectiveness of xamoterol may be diminished when administered concurrently with acebutolol
Combining levobetaxolol and acebutolol can diminish levobetaxolol’s metabolism
When levobupivacaine and acebutolol are combined, the risk or seriousness of adverse events will rise
When domeperidone and acebutolol is used together, this leads to reduction in the domeperidone’s metabolism
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
When ponesimod is used together with acebutolol, this leads to enhanced risk or seriousness of bradycardia
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increasingly adverse effect when combined with cannabis
may have an increasingly adverse effect when combined with cannabis
may have an increased orthostatic hypotensive effect when combined with alpha1-blockers
may have an increased hypoglycemic effect when combined with sulfonylureas
may have an increased hypoglycemic effect when combined with sulfonylureas
When indisulam is used together with acebutolol, this leads to a reduction in acebutolol metabolism
isoxicam may diminish the acebutol's antihypertensive effects
muzolimine may augment the hypotensive activities of acebutolol
acebutolol: it may increase the arrhythmogenic activities of lidoflazine
acebutolol: it may decrease the metabolism of lornoxicam
acebutolol: it may decrease the excretion rate of abacavir CNS depressant
acebutolol: it may decrease the excretion rate of abacavir CNS depressant
acebutolol: it may decrease the excretion rate of abacavir CNS depressant
acebutolol: it may decrease the excretion rate of abacavir CNS depressant
acebutolol: it may decrease the excretion rate of abacavir CNS depressant
acebutolol: it may increase the risk or severity of CNS depression
acebutolol: it may increase the risk or severity of CNS depression
acebutolol: it may increase the risk or severity of CNS depression
sulindac may lower the antihypertensive activities of acebutolol
the arrhythmogenic effects of prenylamine may be intensified when combined with acebutolol
the bradycardic effects of acebutolol may be intensified by ambenonium
acebutolol: it may increase the arrhythmogenic activities of oxprenolol
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
may have an increased hypoglycemic effect when combined with insulins
acebutolol: it may decrease the metabolism of piperazine
acebutolol: it may increase the serum concentration of pipotiazine
flunixin may decrease the antihypertensive activities of acebutolol
niflumic acid may decrease the antihypertensive activities of acebutolol
the metabolism of oxycodone can be decreased when combined with acebutolol
the therapeutic effectiveness of insulin aspart can be increased when used in conjunction with acebutolol
the therapeutic efficacy of insulin pork can be raised when used in combination with acebutolol
using isometheptene in conjunction with acebutolol can reduce the effectiveness of its treatment
there is a additive effect when beta-adrenergic blockers are combined with antiglaucoma agents
there is a additive effect when beta- antiarrhythmics are combined with antiglaucoma agents
acebutolol: it may enhance the orthostatic hypotensive activities of phentolamine
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
amiodarone may enhance the bradycardic effect of beta-blockers
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
may enhance the adverse/toxic effect of lacosamide
it may enhance the serum potassium levels
it enhances the serum potassium levels
it enhances the serum potassium levels
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may enhance the effects of the other by pharmacodynamic synergism
glycopyrrolate inhaled and formoterolÂ
it enhances the serum potassium levels
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
may increase the hypoglycaemic effect
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the effect of hypoglycemia of antidiabetic agents
Beta-blockers increase the concentration of bupivacaine in the serum
Beta-Blockers decrease the efficacy of dobutamine
Beta-Blockers increase the effect of hypertension on epinephrine
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
Beta-Blockers increase the effect of vasoconstriction of ergot derivatives
it increases the effect of bradycardia of Beta-Blockers
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
Beta-Blockers increase the effect of hypoglycemia of insulins
may increase the toxic effect
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
NSAIDs may diminish the effect of beta-blockers
may enhance the antiarrhythmic effect
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may increase the bradycardic effect
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the bradycardic effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the AV-blocking effect of beta-blockers
may enhance the serum concentration of Beta-Blockers
may decrease the bronchodilatory effect
may have an increased hypotensive effect when combined with nifedipine
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may reduce the effect of beta-blockers
may reduce the effect of beta-blockers
may reduce the effect of beta-blockers
may reduce the effect of beta-blockers
may reduce the effect of beta-blockers
may enhance the serum concentration when combined with mepivacaine
may increase the adverse effect of Antiarrhythmic Agents
may have an increasingly adverse effect when combined with antiarrhythmic agents (class Ib)
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may increase the bradycardic effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may reduce the bronchodilatory effect
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may enhance the QTc-prolonging effect of each other when combined
may decrease the therapeutic efficacy of each other when combined
pilsicainide hydrochloride increases the risk of arrhythmia when co-administered with other anti-arrhythmic agents
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may decrease the bronchodilatory effect of beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
acebutolol increases the arrhythmogenic properties or action of vernakalant
when etafedrine is combined with acebutolol, its efficacy will decrease
arrhythmogenic effects of agmatine may be enhanced with acebutolol
may decrease the antihypertensive effect when combined with beta-blockers
the antihypertensive effects of acebutolol may be decreased when combined with kebuzone
acebutolol and asunaprevir together can lower acebutolol's metabolism
combining acebutolol with carbimazole may increase the risk or severity of adverse effects
acebutolol may enhance the vasoconstricting activities of dihydroergocristine
the vasoconstricting activity of dihydroergocornine may be increased with acebutolol
the hypertensive activity of acebutolol may be reduced
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increasingly adverse effect when combined with cannabis
may have an increasingly adverse effect when combined with cannabis
the serum levels of potassium may be increased
the hyperkalemic activity of acebutolol may be increased
the therapeutic activity of acebutolol may be decreased
the bradycardic activity of acebutolol may be increased
the bradycardic activity of acebutolol may be increased
the bradycardic activity of acebutolol may be increased
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
may increase the serum concentration of each other when it is combined
the bradycardic activity of acebutolol may be increased
the bradycardic activity of acebutolol may be increased
the bradycardic effects of acebutolol may be intensified by ambenonium
cinchocaine has the potential to amplify the bradycardic activities of acebutolol
the serum levels of acebutolol may be increased
the therapeutic activity of acebutolol may be reduced
the antihypertensive activity of acebutolol may be decreased
the antihypertensive activity of acebutolol may be reduced
the antihypertensive activity of acebutolol may be reduced
the antihypertensive effect of acebutolol may be reduced
indobufen: it may decrease the antihypertensive activities of acebutolol
the therapeutic effect of pf-00610355 may be reduced
the therapeutic effect of acebutolol may be increased
the therapeutic activity of acebutolol may be increased
the hypotensive activity of acebutolol may be increased
the hypotensive activity of candoxatril may be increased
clonixin may lessen acebutolol's protective effects against hypertension
tepoxalin may reduce the antihypertensive activities of acebutolol
the antihypertensive activity of acebutolol may be reduced
an increase in hypotensive activity of acebutolol may be seen
When acebutolol is used together with oliceridine, this leads to reduction in oliceridine’s metabolism
the rate of metabolism of abiraterone may be decreased
spironolactone and hydrochlorothiazide
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
may increase the toxicity of the drug by decreasing the renal clearance
choline magnesium trisalicylateÂ
choline magnesium trisalicylate may lessen the antihypertensive activities of acebutolol
may decrease the antihypertensive effect when combined with beta-blockers
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
may enhance the serum concentration when combined with propranolol
the therapeutic effects of acebutolol may be enhanced
may enhance the effects of the other by pharmacodynamic synergism
Mechanism of action
A beta-adrenergic receptor blocker (beta-blocker) blocks the binding of norepinephrine and epinephrine to beta-adrenergic receptors in the heart and blood vessels. This reduces heart rate, contractility (force of heart muscle contraction), cardiac output, and decreased blood pressure
Spectrum
It has a limited spectrum of activity and is primarily indicated for the treatment of hypertension (high blood pressure), angina pectoris (chest pain due to reduced blood flow to the heart), and prophylaxis after myocardial infarction (heart attack). It can also treat irregular heartbeats (arrhythmias), such as supraventricular tachycardia
Frequency defined:
>10%
Fatigue
1-10%
Headache
Diarrhea
Dyspepsia
Flatulence
Abdominal pain
Chest pain
Edema
Hypotension
Myalgia
Pruritis
Vomiting
Dizziness
Constipation
Dyspnea
Nausea
Insomnia
Bradycardia
Dysuria
Heart failure
Impotence
Pharyngitis
<1%
Hepatotoxicity
Frequency not defined
Depression
Raynaud’s phenomenon
Bronchospasm
Contraindications
Caution
Pregnancy consideration: It should not be used during pregnancy, as it can cross the placenta and cause harm to the foetus
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology
It is a beta-adrenergic receptor blocker (beta-blocker) that belongs to the non-selective beta-blocker class of drugs. It works by blocking the binding of norepinephrine and epinephrine to beta-adrenergic receptors in the heart and blood vessels. This reduces heart rate, contractility (force of heart muscle contraction), and cardiac output and decreases blood pressure
Pharmacodynamics
The pharmacodynamic effects of acebutolol include a reduction in heart rate, contractility (force of heart muscle contraction), cardiac output, and a decrease in blood pressure. These effects inhibit the sympathetic nervous system, which usually stimulates the heart and blood vessels.
In addition to its effects on the cardiovascular system, acebutolol can also have other pharmacodynamic effects, including a reduction in insulin release and an increase in the release of glucose from the liver. The drug may also have some broncho-dilating effects, although these effects are generally not as pronounced as those seen with selective beta-2 adrenergic receptor blockers
Pharmacokinetics
Administration
Patient information leaflet
Generic Name: acebutolol
Pronounced: [ A-se-BUE-toe-lol ]
Why do we use acebutolol?
It is a medication that is used for the treatment of several conditions, including:
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
